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1051 Regional low-flow perfusion improves neurologic outcome compared with
deep hypothermic circulatory arrest in neonatal piglets
Richard J. Myung, MD, Matus Petko, MD, Alexander R. Judkins, MD, Gregory Schears, MD,
Richard F. Ittenbach, PhD, Robert J. Waibel, BS, and William M. DeCampli, MD, PhD,
Philadelphia, Pa
Regional low-flow perfusion, used as an alternative to deep hypothermic circulatory arrest
during congenital heart surgery, decreases neuronal injury and improves early postoperative
neurologic recovery in a chronic neonatal piglet model.
1058 Inhaled prostacyclin is safe, effective, and affordable in patients with
pulmonary hypertension, right heart dysfunction, and refractory hypoxemia
after cardiothoracic surgery
Charl J. De Wet, MBChB, David G. Affleck, MD, Eric Jacobsohn, MBChB, MHPE, FRCPC,
Michael S. Avidan, MBBCh, Heidi Tymkew, MHS, Laureen L. Hill, MD, Paul B. Zanaboni,
MD, PhD, Nader Moazami, MD, and Jennifer R. Smith, PharmD, St Louis, Mo
We prospectively enrolled 126 cardiothoracic surgical patients with pulmonary hypertension,
right ventricular dysfunction, or refractory hypoxemia to receive inhaled prostacyclin. This
therapy was shown to be safe and effective. Compared with inhaled nitric oxide, the calculated
potential cost savings were significant.
1068 The Coapsys device to treat functional mitral regurgitation: In vivo long-
term canine study
Masahiro Inoue, MD, PhD, Patrick M. McCarthy, MD, Zoran B. Popovic´, MD, Kazuyoshi Doi,
MD, Soren Schenk, MD, Hassan Nemeh, MD, Yoshio Ootaki, MD, PhD, Michael W. Kopcak,
Jr, BA, Raymond Dessoffy, AA, James D. Thomas, MD, and Kiyotaka Fukamachi, MD, PhD,
Cleveland, Ohio
The Coapsys device (Myocor, Inc, Maple Grove, Minn) significantly decreased mitral
regurgitation in a canine pacing-induced functional mitral regurgitation model and maintained
the results chronically.
General Thoracic
Surgery
(GTS)
1078 Combined proteasome and histone deacetylase inhibition in non–small cell
lung cancer
Chadrick E. Denlinger, MD, Michael D. Keller, BS, Marty W. Mayo, PhD, R. Michael Broad,
PhD, and David R. Jones, MD, Charlottesville, Va
Non–small cell lung cancer appears to be resistant to histone deacetylase inhibitors in part
because of activation of the antiapoptotic transcription factor nuclear factor B. Combined
proteasome and histone deacetylase inhibition markedly enhances apoptotic cell death in non–
small cell lung cancer. Future investigations with this novel combination are warranted.
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